The treatment of systemic-onset JIA specifically has developed to include targeted therapies for interleukin-1 and interleukin-6, as these cytokines are recognized as playing an important role in the development of inflammation [29]. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.